This firm is the most asymmetric risk profile of the companies on the site as of July 2021. NWBO will either go to near zero or it will increase multiple times. DC VAX-L has been in clinical trials for over a decade. With the trial complete in 2020 and the data lock, investors are looking for a pending report. What tips the scales for me are two aspects: (1) the asymmetric risk to reward I see in this stock when buying near $1.50 (2) the investment of funding into a manufacturing facility in Swaston, UK that is well publicized. The second item hints that the company believes strongly enough in a future approval that they are ramping up for manufacturing.
